Background
Despite effective antiretroviral therapies (ART), people living with HIV (PWH) have elevated rates of inflammation, hypercoagulation, and associated comorbidities. Gut damage correlates with immune dysfunction in PWH, but precise etiologies remain poorly defined. Due to heterogeneity of clinical cohorts, generalizable metabolomic studies from PWH are limited but can be augmented with animal models.
Methods
Eighteen pigtailed macaques were infected with 300 TCID SIVsab. Beginning on day 48, six were administered ART (DTG+3TC+TDF) daily. Plasma metabolic profiling was performed by ultra-high performance liquid chromatography/tandem mass spectrometry. CBCs, serum chemistries, Luminex, and immunophenotyping were performed longitudinally, including at pre-, acute, setpoint, and chronic infection. Statistics included Wilcoxon signed-rank tests with two-stage step-up correction (1% FDR), principal component analysis, and Pearson correlation.
Results
125 metabolites were modified by acute infection (q<0.0091) and 42 at setpoint (q<0.0093), with 31 persistently changed at both. Six subpathways had multiple metabolite discoveries at both timepoints. Bile acid dysregulation included acute decreases in primary bile acids, followed by increased conjugated bile salts. These correlated with aspartate aminotransferase (all p<0.01), suggesting cholestasis and leakage into blood (Fig 1A). Vitamin A compounds (5 discoveries) were persistently reduced and correlated with CD4+ T cell counts (p<0.001), T cell activation (p<0.001), hypercoagulability (p<0.001), and macrophage activation (p<0.01) (Fig 1B). Purine changes involved upregulation of xanthine oxidase (XO) and correlated with liver damage, hypercoagulability, and macrophage activation (all p<0.001) (Fig 1C). Tryptophan metabolism was highly dysregulated (6 discoveries) and correlated with disease progression markers (several p<0.001) (Fig 1D). Reduced dipeptides (five discoveries) negatively correlated with CD4+ T cell counts (all p<0.001), consistent with CD26+ T cell depletion (Fig 1E). Of those listed, ART was insufficient to recover pro-vitamin A levels.
Conclusions
Five of six metabolic subpathways modified by SIV were highly associated with mucosal immune dysregulations and could be leveraged for development of therapeutic interventions aimed at reducing HIV-associated comorbidities, such as XO or IDO1 inhibitors and retinoid agonists. Loss of DPP-4 (CD26) should be examined in the context of emerging incretin-based therapies (GLPs) for PWH.
Table or Figure
